Localization and functional analysis of the LARGE family of glycosyltransferases: significance for muscular dystrophy.

The dystroglycanopathies are a novel group of human muscular dystrophies due to mutations in known or putative glycosyltransferase enzymes. They share the common pathological feature of a hypoglycosylated form of alpha-dystroglycan, diminishing its ability to bind extracellular matrix ligands. The LARGE glycosyltransferase is mutated in both the myodystrophy mouse and congenital muscular dystrophy type 1D (MDC1D). We have transfected various cell lines with a variety of LARGE expression constructs in order to characterize their subcellular localization and effect on alpha-dystroglycan glycosylation. Wild-type LARGE co-localized with the Golgi marker GM130 and stimulated the production of highly glycosylated alpha-dystroglycan (hyperglycosylation). MDC1D mutants had no effect on alpha-dystroglycan glycosylation and failed to localize correctly, confirming their pathogenicity. The two predicted catalytic domains of LARGE contain three conserved DxD motifs. Systematically mutating each of these motifs to NNN resulted in the mislocalization of one construct, while all failed to have any effect on alpha-dystroglycan glycosylation. A construct lacking the transmembrane domain also failed to localize at the Golgi apparatus. These results indicate that LARGE needs to both physically interact with alpha-dystroglycan and function as a glycosyltransferase in order to stimulate alpha-dystroglycan hyperglycosylation. We have also cloned and overexpressed a homologue of LARGE, glycosyltransferase-like 1B (GYLTL1B). Like LARGE it localized to the Golgi apparatus and stimulated alpha-dystroglycan hyperglycosylation. These results suggest that GYLTL1B may be a candidate gene for muscular dystrophy and that its overexpression could compensate for the deficiency of both LARGE and other glycosyltransferases.

[1]  Gerhard K. H. Przemeck,et al.  Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[2]  K. Campbell,et al.  LARGE can functionally bypass α-dystroglycan glycosylation defects in distinct congenital muscular dystrophies , 2004, Nature Medicine.

[3]  Susan C. Brown,et al.  Glycosylation eases muscular dystrophy , 2004, Nature Medicine.

[4]  K. Campbell,et al.  Molecular Recognition by LARGE Is Essential for Expression of Functional Dystroglycan , 2004, Cell.

[5]  Susan C. Brown,et al.  Defective glycosylation in congenital muscular dystrophies , 2004, Current opinion in neurology.

[6]  Susan C. Brown,et al.  Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan. , 2003, Human molecular genetics.

[7]  H. Freeze,et al.  Glycobiology of neuromuscular disorders. , 2003, Glycobiology.

[8]  K. Campbell,et al.  Dystrophin-Glycoprotein Complex: Post-translational Processing and Dystroglycan Function* 210 , 2003, The Journal of Biological Chemistry.

[9]  J. Hewitt,et al.  Mutation of Large, which encodes a putative glycosyltransferase, in an animal model of muscular dystrophy. , 2002, Biochimica et biophysica acta.

[10]  C. Walsh,et al.  Mutations in the O-mannosyltransferase gene POMT1 give rise to the severe neuronal migration disorder Walker-Warburg syndrome. , 2002, American journal of human genetics.

[11]  H. Lassmann,et al.  Skeletal, cardiac and tongue muscle pathology, defective retinal transmission, and neuronal migration defects in the Large(myd) mouse defines a natural model for glycosylation-deficient muscle - eye - brain disorders. , 2002, Human molecular genetics.

[12]  R. Hampton.  ER-associated degradation in protein quality control and cellular regulation. , 2002, Current opinion in cell biology.

[13]  K. Campbell,et al.  Post-translational disruption of dystroglycan–ligand interactions in congenital muscular dystrophies , 2002, Nature.

[14]  E. Berger.  Ectopic localizations of Golgi glycosyltransferases. , 2002, Glycobiology.

[15]  Susan C. Brown,et al.  Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan. , 2001, American journal of human genetics.

[16]  Susan C. Brown,et al.  Mutations in the fukutin-related protein gene (FKRP) identify limb girdle muscular dystrophy 2I as a milder allelic variant of congenital muscular dystrophy MDC1C. , 2001, Human molecular genetics.

[17]  M. Mizuno,et al.  Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. , 2001, Developmental cell.

[18]  J. Hewitt,et al.  Mutant glycosyltransferase and altered glycosylation of alpha-dystroglycan in the myodystrophy mouse. , 2001, Nature genetics.

[19]  S. Munro,et al.  The Notch signalling regulator Fringe acts in the Golgi apparatus and requires the glycosyltransferase signature motif DxD , 2000, Current Biology.

[20]  K. Campbell,et al.  Biosynthesis of dystroglycan: processing of a precursor propeptide , 2000, FEBS letters.

[21]  T. Endo.  O-mannosyl glycans in mammals. , 1999, Biochimica et biophysica acta.

[22]  K. Campbell,et al.  Dystroglycan inside and out. , 1999, Current opinion in cell biology.

[23]  I. Dunham,et al.  The human LARGE gene from 22q12.3-q13.1 is a new, distinct member of the glycosyltransferase gene family. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[24]  K. Campbell,et al.  Dystroglycan in development and disease. , 1998, Current opinion in cell biology.

[25]  S. Munro,et al.  A Common Motif of Eukaryotic Glycosyltransferases Is Essential for the Enzyme Activity of Large Clostridial Cytotoxins* , 1998, The Journal of Biological Chemistry.

[26]  I. Kanazawa,et al.  An ancient retrotransposal insertion causes Fukuyama-type congenital muscular dystrophy , 1998, Nature.

[27]  S. Munro,et al.  Activity of the yeast MNN1 alpha-1,3-mannosyltransferase requires a motif conserved in many other families of glycosyltransferases. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[28]  C. Whitfield,et al.  The Assembly System for the Lipopolysaccharide R2 Core-type ofEscherichia coli Is a Hybrid of Those Found inEscherichia coli K-12 and Salmonella enterica , 1998, The Journal of Biological Chemistry.

[29]  T. Nishi,et al.  Expression cloning of cDNA encoding a human beta-1,3-N-acetylglucosaminyltransferase that is essential for poly-N-acetyllactosamine synthesis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Daniels,et al.  Dystroglycan is essential for early embryonic development: disruption of Reichert's membrane in Dag1-null mice. , 1997, Human molecular genetics.

[31]  K. Colley,et al.  Golgi localization of glycosyltransferases: more questions than answers. , 1997, Glycobiology.

[32]  M. Gentzsch,et al.  The PMT gene family: protein O‐glycosylation in Saccharomyces cerevisiae is vital. , 1996, The EMBO journal.

[33]  U. Francke,et al.  Human dystroglycan: skeletal muscle cDNA, genomic structure, origin of tissue specific isoforms and chromosomal localization. , 1993, Human molecular genetics.

[34]  O. Ibraghimov-Beskrovnaya,et al.  Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix , 1992, Nature.

[35]  J. Ervasti,et al.  Membrane organization of the dystrophin-glycoprotein complex , 1991, Cell.

[36]  P. Lane,et al.  Myodystrophy, a new myopathy on chromosome 8 of the mouse. , 1976, The Journal of heredity.